应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03069 华夏恒生生科
交易中 11-17 15:33:49
14.370
-0.180
-1.24%
最高
14.550
最低
14.180
成交量
549.80万
今开
14.550
昨收
14.550
日振幅
2.54%
总市值
37.14亿
流通市值
37.14亿
总股本
2.58亿
成交额
7,894万
换手率
2.13%
流通股本
2.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
中国医药(600056)披露子公司获得化学原料药上市申请批准通知书,11月16日股价上涨0.94%
证券之星 · 11-16 22:42
中国医药(600056)披露子公司获得化学原料药上市申请批准通知书,11月16日股价上涨0.94%
股市必读:中国医药(600056)11月13日董秘有最新回复
证券之星 · 11-16 01:54
股市必读:中国医药(600056)11月13日董秘有最新回复
中国医药:公司将于11月19日召开2026年第三季度业绩说明会
证券之星 · 11-13
中国医药:公司将于11月19日召开2026年第三季度业绩说明会
百克生物:公司是一家专业从事人用疫苗研发、生产、销售的高科技生物制药企业
证券之星 · 11-13
百克生物:公司是一家专业从事人用疫苗研发、生产、销售的高科技生物制药企业
中国医药新注册《穿透式监管业务中台系统V1.0》项目的软件著作权
证券之星 · 11-13
中国医药新注册《穿透式监管业务中台系统V1.0》项目的软件著作权
股市必读:中国医药(600056)11月12日董秘有最新回复
证券之星 · 11-13
股市必读:中国医药(600056)11月12日董秘有最新回复
澳洲恩吉斯养老金首席投资官Ben Squires:中国生物科技企业已跻身全球一流水平,看好中国资产长期投资机会
长三角资本局 · 11-12
澳洲恩吉斯养老金首席投资官Ben Squires:中国生物科技企业已跻身全球一流水平,看好中国资产长期投资机会
股市必读:中国医药(600056)11月11日董秘有最新回复
证券之星 · 11-12
股市必读:中国医药(600056)11月11日董秘有最新回复
中国医药:公司坚持稳中求进,以科技创新为引领
证券之星 · 11-11
中国医药:公司坚持稳中求进,以科技创新为引领
华夏港美人工智能ETF(03140)正式纳入互联互通 内地合资格投资者迎布局港美AI 产业链机会
智通财经 · 11-11
华夏港美人工智能ETF(03140)正式纳入互联互通 内地合资格投资者迎布局港美AI 产业链机会
加快实业化布局,中国医药以科创领航、规范提质夯实发展根基
同花顺 · 11-10
加快实业化布局,中国医药以科创领航、规范提质夯实发展根基
股市必读:中国医药新发布《第十届董事会第9次会议决议公告》
证券之星 · 11-10
股市必读:中国医药新发布《第十届董事会第9次会议决议公告》
中国医药(600056)披露2027年度“提质增效重回报”2.0行动方案,11月09日股价下跌0.78%
证券之星 · 11-09
中国医药(600056)披露2027年度“提质增效重回报”2.0行动方案,11月09日股价下跌0.78%
国药控股:与中国医药集团签订二零二六年框架协议
南方财经网 · 11-09
国药控股:与中国医药集团签订二零二六年框架协议
九典制药:成为中国医药行业领跑者之一
证券之星 · 11-06
九典制药:成为中国医药行业领跑者之一
国盛证券:中国医药产业创新效率居世界前列 把握AI赋能下创新产业链及内外需共振机遇
智通财经 · 11-04
国盛证券:中国医药产业创新效率居世界前列 把握AI赋能下创新产业链及内外需共振机遇
【券商聚焦】中信建投:中国医药资产全球性价比凸显,内外协同空间广阔
金吾财讯 · 11-02
【券商聚焦】中信建投:中国医药资产全球性价比凸显,内外协同空间广阔
股市必读:中国医药三季报 - 第三季度单季净利润同比下降73.88%
证券之星 · 11-02
股市必读:中国医药三季报 - 第三季度单季净利润同比下降73.88%
股市必读:中国医药新发布《关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-30
股市必读:中国医药新发布《关于召开2026年第三季度业绩说明会的公告》
图解中国医药三季报:第三季度单季净利润同比下降73.88%
证券之星 · 10-30
图解中国医药三季报:第三季度单季净利润同比下降73.88%
加载更多
公司概况
公司名称:
华夏恒生生科
所属市场:
SEHK
上市日期:
--
主营业务:
子基金的投资目标为提供紧贴指数表现的投资回报(未扣除费用及开支)。并不保证子基金能否达致其投资目标。子基金的指数经证监会事先批准及知会基金单位持有人后可更改。
发行价格:
--
{"stockData":{"symbol":"03069","market":"HK","secType":"STK","nameCN":"华夏恒生生科","latestPrice":14.37,"timestamp":1794900814846,"preClose":14.55,"halted":0,"volume":5498018,"delay":0,"changeRate":-0.012371134020618658,"floatShares":258459213,"shares":258459213,"eps":0,"marketStatus":"交易中","change":-0.18,"latestTime":"11-17 15:33:49","open":14.55,"high":14.55,"low":14.18,"amount":78940096,"amplitude":0.02543,"askPrice":14.38,"askSize":311600,"bidPrice":14.36,"bidSize":17600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794903000000},"marketStatusCode":2,"adr":0,"listingDate":1615996800000,"exchange":"SEHK","adjPreClose":14.55,"sharesOutstanding":237400000,"nav":14.493,"aum":0,"dividendRate":0.003479,"bidAskSpread":0,"openAndCloseTimeList":[[1794879000000,1794888000000],[1794891600000,1794902400000]],"volumeRatio":1.073936,"lotSize":100,"spreadScale":3,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03069","defaultTab":"news","newsList":[{"id":"2683643566","title":"中国医药(600056)披露子公司获得化学原料药上市申请批准通知书,11月16日股价上涨0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683643566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683643566?lang=zh_cn&edition=full","pubTime":"2026-11-16 22:42","pubTimestamp":1794840125,"startTime":"0","endTime":"0","summary":"截至2026年11月16日收盘,中国医药报收于8.59元,较前一交易日上涨0.94%,最新总市值为128.5亿元。该股当日开盘8.51元,最高8.6元,最低8.47元,成交额达7580.66万元,换手率为0.59%。近日,中国医药发布公告称,其全资子公司天方药业有限公司收到国家药监局核准签发的佩玛贝特化学原料药上市申请批准通知书,批准该原料药在国内上市制剂中使用。本次获批有助于拓展公司产品领域,完善心血管领域原料药布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600036524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0028","03069","BK0185","BK0188","BK0175","BK0250","BK1610","600056","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683520326","title":"股市必读:中国医药(600056)11月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2683520326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683520326?lang=zh_cn&edition=full","pubTime":"2026-11-16 01:54","pubTimestamp":1794765254,"startTime":"0","endTime":"0","summary":"截至2026年11月13日收盘,中国医药报收于8.51元,下跌2.63%,换手率1.08%,成交量16.22万手,成交额1.39亿元。董秘最新回复投资者: 经营目标系根据公司实际经营业绩基础、公司战略规划及市场环境和行业政策的影响,综合考虑各项现实基础、公司经营能力等相关基本假设的前提下制定。交易信息汇总资金流向11月13日主力资金净流出1211.99万元,占总成交额8.69%;游资资金净流入1779.0万元,占总成交额12.76%;散户资金净流出567.01万元,占总成交额4.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600000650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0028","BK0082","BK0175","600056","BK0250","BK0010","03069","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683957604","title":"中国医药:公司将于11月19日召开2026年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2683957604","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683957604?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:39","pubTimestamp":1794562773,"startTime":"0","endTime":"0","summary":"证券之星消息,中国医药(600056)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司三季度是否会开业绩说明会,投资者急着与公司交流.中国医药回复:您好!公司将于11月19日召开2026年第三季度业绩说明会,也欢迎您随时致电公司股民热线电话010-67164267进行直接交流。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300031302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","03069","BK1610","BK0010","BK0188","BK0185","600056","BK0028","BK0082","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683578637","title":"百克生物:公司是一家专业从事人用疫苗研发、生产、销售的高科技生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2683578637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683578637?lang=zh_cn&edition=full","pubTime":"2026-11-13 16:18","pubTimestamp":1794557892,"startTime":"0","endTime":"0","summary":"公司目前拥有水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等已获批的疫苗产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300027854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1610","BK0239","688276","159646","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683511826","title":"中国医药新注册《穿透式监管业务中台系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2683511826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683511826?lang=zh_cn&edition=full","pubTime":"2026-11-13 02:36","pubTimestamp":1794508576,"startTime":"0","endTime":"0","summary":"证券之星消息,近日中国医药(600056)新注册了《穿透式监管业务中台系统V1.0》项目的软件著作权。今年以来中国医药新注册软件著作权11个。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了8094.94万元,同比增23.34%。通过天眼查大数据分析,中国医药健康产业股份有限公司共对外投资了30家企业,参与招投标项目848次;财产线索方面有商标信息5条,专利信息4条,著作权信息10条;此外企业还拥有行政许可15个。数据来源:企查查以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","159180","BK0188","BK0010","BK0082","BK0250","600056","BK0175","BK1610","BK0185","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683313511","title":"股市必读:中国医药(600056)11月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2683313511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683313511?lang=zh_cn&edition=full","pubTime":"2026-11-13 02:34","pubTimestamp":1794508454,"startTime":"0","endTime":"0","summary":"截至2026年11月12日收盘,中国医药报收于8.74元,上涨0.23%,换手率0.87%,成交量13.01万手,成交额1.13亿元。董秘最新回复投资者: 公司连年度目标都无法完成(假定的),请问公司在干什么?当日关注点交易信息汇总:11月12日主力资金净流入404.94万元,游资资金净流入1235.86万元,散户资金净流出1640.8万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069","BK0188","BK0082","BK0028","BK1610","BK0175","BK0250","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682550700","title":"澳洲恩吉斯养老金首席投资官Ben Squires:中国生物科技企业已跻身全球一流水平,看好中国资产长期投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2682550700","media":"长三角资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682550700?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:04","pubTimestamp":1794470640,"startTime":"0","endTime":"0","summary":"澳洲恩吉斯养老金首席投资官Ben Squires在会上表示,中国经济具有较强韧性,产业体系的深度是中国经济韧性的重要来源。Ben Squires表示,其所在机构投资中国市场已超过16年。Ben Squires强调,当前中国资本市场的投资便利性持续提升,相关机制不断完善将有助于吸引更多国际资本。对于中国未来的投资机会及长期回报前景,他持积极乐观态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/csjzbj/2026-11-12/doc-iniynifc1779932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1610","KURE","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682581383","title":"股市必读:中国医药(600056)11月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2682581383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682581383?lang=zh_cn&edition=full","pubTime":"2026-11-12 02:06","pubTimestamp":1794420377,"startTime":"0","endTime":"0","summary":"截至2026年11月11日收盘,中国医药报收于8.72元,下跌1.02%,换手率0.81%,成交量12.07万手,成交额1.05亿元。董秘最新回复投资者: 请问公司三季度是否会开业绩说明会,投资者急着与公司交流董秘: 您好!请问公司为了成为医药先进制造国内一流领军企业做了什么工作董秘: 您好!当日关注点交易信息汇总:11月11日主力资金净流出395.08万元,占总成交额3.75%;游资资金净流入1281.91万元,占总成交额12.17%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200002208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0188","BK1610","BK0010","BK0250","BK0175","600056","BK0185","BK0028","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682370024","title":"中国医药:公司坚持稳中求进,以科技创新为引领","url":"https://stock-news.laohu8.com/highlight/detail?id=2682370024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682370024?lang=zh_cn&edition=full","pubTime":"2026-11-11 18:00","pubTimestamp":1794391236,"startTime":"0","endTime":"0","summary":"证券之星消息,中国医药(600056)11月11日在投资者关系平台上答复投资者关心的问题。投资者提问:公司力争到2030年成为医药先进制造国内一流领军企业。现在已经是2026年10月中了,一个月又过去了,时间紧、任务重。请问公司是否已有匹配国内一流领军企业的技术能力和产品?请问公司为了成为医药先进制造国内一流领军企业做了什么工作中国医药回复:您好!公司坚持稳中求进,以科技创新为引领,将持续通过完善科技创新布局、业务转型升级、管理提升等举措,努力提升经营质效,为股东创造长期价值。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100036535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1610","BK0175","BK0082","BK0188","03069","BK0028","BK0250","600056","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682553324","title":"华夏港美人工智能ETF(03140)正式纳入互联互通 内地合资格投资者迎布局港美AI 产业链机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2682553324","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682553324?lang=zh_cn&edition=full","pubTime":"2026-11-11 11:50","pubTimestamp":1794369036,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华夏基金(香港)有限公司旗下华夏港美人工智能ETF已于11月9日正式纳入ETF互联互通南向通标的,开放港股通交易权限,入通后首日市场成交显著放量,南向资金参与热度抬升。此次标的扩容,进一步完善了华夏基金(香港)互联互通产品线布局,为内地合资格投资者提供优秀的跨市场配置工具,便捷布局港美人工智能产业机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03417","AIPO","AGIX","02837","03032","07226","ARTY","07552","03088","83140","03069","09088","09140","CHAT","BK1610","03067","QTOC","VTHR","03140","03033","09067","03423","03403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682236136","title":"加快实业化布局,中国医药以科创领航、规范提质夯实发展根基","url":"https://stock-news.laohu8.com/highlight/detail?id=2682236136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682236136?lang=zh_cn&edition=full","pubTime":"2026-11-10 15:12","pubTimestamp":1794294720,"startTime":"0","endTime":"0","summary":"作为国内医药健康产业领域的央企代表,中国医药健康产业股份有限公司(以下简称“中国医药”或“公司”)于近日正式发布《2027年度“提质增效重回报”2.0行动方案》,对外传递出聚焦主业、强 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261110/c681653407.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261110/c681653407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0188","159982","BK0028","BK0250","BK0175","BK0010","600056","BK0185","BK1610","03069","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682333446","title":"股市必读:中国医药新发布《第十届董事会第9次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682333446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682333446?lang=zh_cn&edition=full","pubTime":"2026-11-10 02:56","pubTimestamp":1794250606,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘,中国医药报收于8.86元,下跌0.78%,换手率0.55%,成交量8.16万手,成交额7259.74万元。公司公告汇总:第十届董事会第9次会议全票通过《关于公司“十五五”发展规划的议案》及《关于公司2027年度“提质增效重回报”2.0行动方案的议案》。公司公告汇总:2027年度“提质增效重回报”2.0行动方案明确研发平台实质化运行不少于4个、新产品销售收入占比达7%、分红比例维持归母净利润的30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000002998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK1610","600056","BK0185","03069","BK0188","BK0250","BK0028","BK0082","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682381625","title":"中国医药(600056)披露2027年度“提质增效重回报”2.0行动方案,11月09日股价下跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682381625","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682381625?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:32","pubTimestamp":1794234722,"startTime":"0","endTime":"0","summary":"截至2026年11月9日收盘,中国医药报收于8.86元,较前一交易日下跌0.78%,最新总市值为132.53亿元。该股当日开盘8.96元,最高8.98元,最低8.86元,成交额达7259.74万元,换手率为0.55%。近日,中国医药健康产业股份有限公司发布《2027年度“提质增效重回报”2.0行动方案》公告。公司近三年营业收入分别为388.24亿元、352.43亿元、353.62亿元,扣非归母净利润持续回升。2027年目标包括研发平台实质化运行不少于4个、新产品销售收入占比达7%、分红比例保持归母净利润的30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900024311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","BK0185","BK1610","BK0250","03069","BK0188","600056","BK0028","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682386166","title":"国药控股:与中国医药集团签订二零二六年框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2682386166","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682386166?lang=zh_cn&edition=full","pubTime":"2026-11-09 21:28","pubTimestamp":1794230882,"startTime":"0","endTime":"0","summary":"21财经11月9日电,国药控股(01099.HK)公告,公司于2026年11月9日与中国医药集团(简称“国药集团”)签订《二零二六年采购框架协议》《二零二六年销售框架协议》《二零二六年金融服务框架协议》《二零二六年EPC总承包服务框架协议》及《二零二六年保理服务框架协议》,协议有效期自2027年1月1日起至2029年12月31日止,为期三年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926518481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926518481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640798160.USD","BK0185","01099","BK1197","600056","BK0010","BK1500","BK1515","BK1610","LU1115378108.SGD","BK0028","BK0188","BK0250","03069","BK0175","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681653882","title":"九典制药:成为中国医药行业领跑者之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2681653882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681653882?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:03","pubTimestamp":1793926995,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)11月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司对公司未来发展有没有奋斗的目标?比如成为五百亿市值龙头,千亿市值大公司之类的。九典制药回复:尊敬的投资者您好,公司的发展愿景是成为中国医药行业领跑者之一。公司始终专注于主业经营,致力于持续提升研发创新能力、丰富产品管线、夯实核心竞争力,努力推动公司高质量、可持续发展。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600056","BK0185","BK1610","BK0188","BK0239","300705","BK0175","BK0250","03069","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680083899","title":"国盛证券:中国医药产业创新效率居世界前列 把握AI赋能下创新产业链及内外需共振机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2680083899","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680083899?lang=zh_cn&edition=full","pubTime":"2026-11-04 11:43","pubTimestamp":1793763806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国盛证券发布研报称,中国在研新药数量约占全球30%,位列全球第二,中国医药产业创新效率居世界前列。AI赋能带来创新药产业链研发实现加速跨越AI驱动药物研发需求快速增长,客户从单一采购转向端到端解决方案,提升黏性与收入可持续性。AI药物发现正在接近行业发展的一个重要拐点。部分医疗器械公司已现业绩拐点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VTHR","BK0052","BK1610","BK0185","002670","CHAT","BK0188","QTOC","BK0082","AIPO","03069","ARTY","600056","BK0250","AGIX","BK0276","BK0175","BK0010","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投:中国医药资产全球性价比凸显,内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称,2026年欧洲内科肿瘤学会 中,中国创新药在多瘤种领域全面发力,众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指,中国医药具有“创新升级+供应链韧性”优势,2025年创新药海外授权首付款大幅超去年全年,器械也在积极探索出海路径。美国主导早期研发与高端定价,但跨国药企专利悬崖下需求旺盛,中国资产全球性价比凸显,内外协同空间广阔。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","601066","BK1207","LU0588546209.SGD","BK0188","BK1100","SG9999014674.SGD","LU0307460666.USD","LU0417516902.SGD","LU1251922891.USD","09688","09926","LU2399975544.HKD","01789","IE00BPRC5H50.USD","LU0348825331.USD","LU1720050803.USD","02268","LU0561508036.HKD","LU2476274308.USD","02367","03069","LU0540923850.HKD","02228","03933","LU0348735423.USD","LU0348766576.USD","LU0348783233.USD","BK1617","BK1161","LU1969619763.USD","LU2476274720.SGD","LU0228659784.USD","LU2488822045.USD","02196","BK0028","06821","LU0348767384.USD","SG9999004311.SGD","BK1515","600056","BK1610","01530","KURE","01099","KCE","BK1588","LU0634319403.HKD","06160","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680200924","title":"股市必读:中国医药三季报 - 第三季度单季净利润同比下降73.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680200924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680200924?lang=zh_cn&edition=full","pubTime":"2026-11-02 04:56","pubTimestamp":1793566570,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘,中国医药报收于8.85元,下跌0.23%,换手率0.78%,成交量11.61万手,成交额1.02亿元。业绩披露要点:2026年第三季度单季度归母净利润4200.24万元,同比下降73.88%。公司公告汇总:中国医药将于2026年11月19日13:00-14:00召开2026年第三季度业绩说明会。其中第三季度单季度主营收入80.37亿元,同比下降8.86%;单季度归母净利润4200.24万元,同比下降73.88%;单季度扣非净利润3702.49万元,同比下降73.3%;负债率62.37%,投资收益1734.34万元,财务费用1.63亿元,毛利率10.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679023097","title":"股市必读:中国医药新发布《关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2679023097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679023097?lang=zh_cn&edition=full","pubTime":"2026-10-30 06:24","pubTimestamp":1793312683,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘,中国医药报收于8.87元,下跌0.11%,换手率0.51%,成交量7.67万手,成交额6785.27万元。当日关注点交易信息汇总:10月29日主力资金净流出213.76万元,占总成交额3.15%。公司公告汇总:中国医药将于2026年11月19日召开2026年第三季度业绩说明会,通过上证路演中心网络互动方式进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000010231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","03069","BK0082","BK0250","BK1610","BK0175","BK0185","600056","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679876052","title":"图解中国医药三季报:第三季度单季净利润同比下降73.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679876052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679876052?lang=zh_cn&edition=full","pubTime":"2026-10-30 01:07","pubTimestamp":1793293671,"startTime":"0","endTime":"0","summary":"证券之星消息,中国医药2026年三季报显示,前三季度公司主营收入249.89亿元,同比下降3.5%;归母净利润2.91亿元,同比下降35.99%;扣非净利润2.68亿元,同比下降32.13%;其中2026年第三季度,公司单季度主营收入80.37亿元,同比下降8.86%;单季度归母净利润4200.24万元,同比下降73.88%;单季度扣非净利润3702.49万元,同比下降73.3%;负债率62.37%,投资收益1734.34万元,财务费用1.63亿元,毛利率10.42%。财报数据概要请见下图:本文数据来源于中国医药2026年三季报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000003010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0472},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0673},{"period":"6month","weight":0.0754},{"period":"1year","weight":-0.1195},{"period":"ytd","weight":0.0139}],"compareEarnings":[{"period":"1week","weight":-0.0284},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.0674},{"period":"6month","weight":-0.074},{"period":"1year","weight":-0.1226},{"period":"ytd","weight":-0.0732}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"子基金的投资目标为提供紧贴指数表现的投资回报(未扣除费用及开支)。并不保证子基金能否达致其投资目标。子基金的指数经证监会事先批准及知会基金单位持有人后可更改。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040155},{"month":2,"riseRate":0.4,"avgChangeRate":0.03003},{"month":3,"riseRate":0.2,"avgChangeRate":-0.029137},{"month":4,"riseRate":0.833333,"avgChangeRate":0.013346},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.016542},{"month":6,"riseRate":0.5,"avgChangeRate":0.022933},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035744},{"month":8,"riseRate":0.5,"avgChangeRate":-0.011048},{"month":9,"riseRate":0.5,"avgChangeRate":0.034327},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.06257},{"month":11,"riseRate":0.666667,"avgChangeRate":0.04568},{"month":12,"riseRate":0.2,"avgChangeRate":-0.056464}],"exchange":"SEHK","name":"华夏恒生生科","nameEN":"CAM HSBIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华夏恒生生科(03069)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华夏恒生生科(03069)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华夏恒生生科,03069,华夏恒生生科股票,华夏恒生生科股票老虎,华夏恒生生科股票老虎国际,华夏恒生生科行情,华夏恒生生科股票行情,华夏恒生生科股价,华夏恒生生科股市,华夏恒生生科股票价格,华夏恒生生科股票交易,华夏恒生生科股票购买,华夏恒生生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华夏恒生生科(03069)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华夏恒生生科(03069)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}